Baseline AI vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Baseline AI is a healthcare AI platform that helps clinical teams monitor patient deterioration early using machine learning models trained on EHR data and vital sign patterns. HQ: San Francisco.
About
Baseline AI is a clinical AI company developing early warning systems for patient deterioration in hospital settings, using machine learning models trained on electronic health record (EHR) data, vital signs, laboratory results, and nursing assessments to predict which patients are at elevated risk of deterioration before clinically obvious changes occur. The company's models identify patterns in multi-parameter data that precede sepsis onset, respiratory failure, and other acute deteriorations — providing bedside nurses and rapid response teams with earlier warning than traditional vital sign threshold alerts.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.